Statin therapy in metabolic syndrome and hypertension post-JUPITER: What is the value of CRP?

Sridevi Devaraj, David Siegel, Ishwarlal Jialal

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Much evidence supports a pivotal role for inflammation in atherosclerosis. C-reactive protein (CRP), the prototypic marker of inflammation in humans, is a cardiovascular risk marker and may also promote atherogenesis. CRP levels are increased in metabolic syndrome and hypertension and confer increased risk of cardiovascular events in patients in these subgroups. Statins have been shown to lower low-density lipoproteins and CRP independently, and reduce cardiovascular events in subjects with and without metabolic syndrome and hypertension. In this review, we focus on the results from the primary prevention statin trial, Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), which showed reductions in LDL, CRP, and cardiovascular events. Post-JUPITER, the new guidelines will now need to consider recommending high-sensitivity CRP testing to intermediate-risk metabolic syndrome patients and those with hypertension and intermediate risk so that we can better identify candidates at greater risk and reduce cardiovascular burden in these subjects with statin therapy.

Original languageEnglish (US)
Pages (from-to)31-42
Number of pages12
JournalCurrent Atherosclerosis Reports
Volume13
Issue number1
DOIs
StatePublished - Feb 2011

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Primary Prevention
C-Reactive Protein
Hypertension
Atherosclerosis
Inflammation
Therapeutics
LDL Lipoproteins
Rosuvastatin Calcium
Guidelines

Keywords

  • Atherosclerosis
  • CRP
  • Endothelial dysfunction
  • Hypertension
  • Inflammation
  • Metabolic syndrome
  • Monocytes
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Statin therapy in metabolic syndrome and hypertension post-JUPITER : What is the value of CRP? / Devaraj, Sridevi; Siegel, David; Jialal, Ishwarlal.

In: Current Atherosclerosis Reports, Vol. 13, No. 1, 02.2011, p. 31-42.

Research output: Contribution to journalArticle

@article{f3b1890912c54c399cb376836732d9a3,
title = "Statin therapy in metabolic syndrome and hypertension post-JUPITER: What is the value of CRP?",
abstract = "Much evidence supports a pivotal role for inflammation in atherosclerosis. C-reactive protein (CRP), the prototypic marker of inflammation in humans, is a cardiovascular risk marker and may also promote atherogenesis. CRP levels are increased in metabolic syndrome and hypertension and confer increased risk of cardiovascular events in patients in these subgroups. Statins have been shown to lower low-density lipoproteins and CRP independently, and reduce cardiovascular events in subjects with and without metabolic syndrome and hypertension. In this review, we focus on the results from the primary prevention statin trial, Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), which showed reductions in LDL, CRP, and cardiovascular events. Post-JUPITER, the new guidelines will now need to consider recommending high-sensitivity CRP testing to intermediate-risk metabolic syndrome patients and those with hypertension and intermediate risk so that we can better identify candidates at greater risk and reduce cardiovascular burden in these subjects with statin therapy.",
keywords = "Atherosclerosis, CRP, Endothelial dysfunction, Hypertension, Inflammation, Metabolic syndrome, Monocytes, Statins",
author = "Sridevi Devaraj and David Siegel and Ishwarlal Jialal",
year = "2011",
month = "2",
doi = "10.1007/s11883-010-0143-2",
language = "English (US)",
volume = "13",
pages = "31--42",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Statin therapy in metabolic syndrome and hypertension post-JUPITER

T2 - What is the value of CRP?

AU - Devaraj, Sridevi

AU - Siegel, David

AU - Jialal, Ishwarlal

PY - 2011/2

Y1 - 2011/2

N2 - Much evidence supports a pivotal role for inflammation in atherosclerosis. C-reactive protein (CRP), the prototypic marker of inflammation in humans, is a cardiovascular risk marker and may also promote atherogenesis. CRP levels are increased in metabolic syndrome and hypertension and confer increased risk of cardiovascular events in patients in these subgroups. Statins have been shown to lower low-density lipoproteins and CRP independently, and reduce cardiovascular events in subjects with and without metabolic syndrome and hypertension. In this review, we focus on the results from the primary prevention statin trial, Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), which showed reductions in LDL, CRP, and cardiovascular events. Post-JUPITER, the new guidelines will now need to consider recommending high-sensitivity CRP testing to intermediate-risk metabolic syndrome patients and those with hypertension and intermediate risk so that we can better identify candidates at greater risk and reduce cardiovascular burden in these subjects with statin therapy.

AB - Much evidence supports a pivotal role for inflammation in atherosclerosis. C-reactive protein (CRP), the prototypic marker of inflammation in humans, is a cardiovascular risk marker and may also promote atherogenesis. CRP levels are increased in metabolic syndrome and hypertension and confer increased risk of cardiovascular events in patients in these subgroups. Statins have been shown to lower low-density lipoproteins and CRP independently, and reduce cardiovascular events in subjects with and without metabolic syndrome and hypertension. In this review, we focus on the results from the primary prevention statin trial, Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), which showed reductions in LDL, CRP, and cardiovascular events. Post-JUPITER, the new guidelines will now need to consider recommending high-sensitivity CRP testing to intermediate-risk metabolic syndrome patients and those with hypertension and intermediate risk so that we can better identify candidates at greater risk and reduce cardiovascular burden in these subjects with statin therapy.

KW - Atherosclerosis

KW - CRP

KW - Endothelial dysfunction

KW - Hypertension

KW - Inflammation

KW - Metabolic syndrome

KW - Monocytes

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=79551554869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551554869&partnerID=8YFLogxK

U2 - 10.1007/s11883-010-0143-2

DO - 10.1007/s11883-010-0143-2

M3 - Article

C2 - 21046291

AN - SCOPUS:79551554869

VL - 13

SP - 31

EP - 42

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 1

ER -